Clal Biotechnology reported ILS158.39M in Assets for its fiscal quarter ending in December of 2023.





Assets Change Date
Arca Biopharma USD 1.14B 634.91M Jun/2026
aTyr Pharma USD 69.82M 9.83M Jun/2026
Bio Path USD 677K 13K Mar/2026
Brainstorm Cell Therapeutics USD 788K 33K Jun/2026
Cara Therapeutics USD 25.82M 6.26M Mar/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 145.86M 10.71M Mar/2026
Immunic USD 189.74M 165.69M Mar/2026
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
RedHill Biopharma USD 25.34M 6.97M Dec/2025
TherapeuticsMD USD 40.13M 1.96M Jun/2024